Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis

Keratonjunctivitis Clinical Trial

Official title:

Combined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis; a Pilot Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04451239
• Other study ID #: COVID-19 keratoconjunctivitis
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 30, 2020
• Est. completion date: July 2020

Study information

• Verified date: June 2020
• Source: Mansoura University
• Contact: Ameera Abdelhameed, MD
• Phone: 01120090000
• Email: amiragamal287[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.

Description:

COVID-19 patients presenting with acute keratoconjunctivitis will be treated with Topical 1% prednisolone acetate fourTimes daily for 7 days as initial treatment, non-preserved artificial tears four times daily and cyclosporin A 0.5% four times daily .

Twelve patients with COVID-19 Keratoconjunctivitis will be enrolled in this open-label study. Symptoms and findings of the patients before and after treatment were recorded.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 12
• Est. completion date: July 2020
• Est. primary completion date: July 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• COVID-19 Patients with keratoconjunctivitis

Exclusion Criteria:

• associated ocular pathology or disease

• other causes of keratoconjunctivitis for example allergic or herpetic

Related Conditions & MeSH terms

• Keratoconjunctivitis
• Keratonjunctivitis

Intervention

Drug:
• topical steroids and cyclosporin-A
All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .

Locations

Country	Name	City	State
Kuwait	Farawanyia hospital	Kuwait	Farawanyia

Sponsors (2)

Lead Sponsor	Collaborator
Ameera Gamal Abdelhameed	Ministry of Health, Kuwait

Country where clinical trial is conducted

Kuwait, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Symptom improvement	eye itching, foreign body sensation, tearing, redness in the eye and eyelid swelling	10-15 days
Primary	Signs improvement	conjunctival injection, discharge, presence of superficial punctate keratitis (SPK), pseudomembranes on tarsal conjunctiva	10-15 days